Cure HHT is excited to announce that the HHT-HTC Treatment Centers, part of Michigan Medicine Hemophilia and Coagulation Disorders Program, as well as the Indiana Hemophilia & Thrombosis Center, Hemophilia Treatment Center (HTCs) are now operational and accepting new HHT patients! Thanks to a new program proposed by Cure HHT and funded by the CDC, Cure…Learn More >>
Check out the sneak preview of Episode 4 of Few & Far Between, Biorasi’s rare disease podcast, featuring Marianne Clancy – Executive Director at Cure HHT. Listen to the full episode on Wednesday 6/23, HHT Awareness Day! This FREE podcast will be available through the Biorasi website and on all major podcast streaming platforms including…Learn More >>
With your support, Cure HHT has accomplished so much, and the best is yet to come! As we launch our 30th Anniversary Year, we look back at just a few of the many successes that donors like you have made possible! Together, we have built an amazing foundation – expanding expert clinical access, funding research,…Learn More >>
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu Syndrome, is an inherited disease that leads to malformed blood vessels in multiple organs of the body and typically begins with nosebleeds during childhood. HHT can result in serious health problems if not promptly diagnosed and treated. Our mission is to find a cure for HHT while saving the lives and improving the well-being of individuals and families affected by HHT.